Clinical Trials on Hereditary Hemorrhagic Telangiectasia in Russian Federation

Total 246 results

GlaxoSmithKline

Completed

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)

Purpura, Thrombocytopaenic, Idiopathic

United States, Taiwan, Italy, Poland, Peru, Canada, Denmark, Germany, Slovakia, Spain, United Kingdom, New Zealand, China, Greece, Hong Kong, Russian Federation, Austria, Netherlands, Czech Republic, France, India, Ukraine, Tunisia, F... and more
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Hemophilia A

United States, Belgium, France, Norway, Netherlands, Austria, Hungary, Italy, Poland, Portugal, Romania, Russian Federation, Spain, Sweden
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Von Willebrand Disease (VWD)

United States, Italy, Spain, Netherlands, Turkey, France, Austria, Germany, Russian Federation
Principia Biopharma, a Sanofi Company

Recruiting

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (LUNA 3)

Immune Thrombocytopenia

United States, China, Argentina, Australia, Brazil, Canada, France, Hungary, Israel, Korea, Republic of, Mexico, Russian Federation, Singapore, Spain, Thailand, United Kingdom, Austria, Chile, Germany, Italy, Japan, Netherlands, Norway and more
Baxalta now part of Shire

Completed

BAX 326 (rFIX) Continuation Study

Hemophilia B

Taiwan, Colombia, Argentina, Brazil, Bulgaria, Chile, Czechia, India, Ireland, Italy, Japan, Poland, Romania, Russian Federation, Sweden, Ukraine, United Kingdom
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
Green Cross Corporation
Atlantic Research Group

Unknown

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

Hemophilia A

United States, Canada, New Zealand, Poland, Russian Federation, Ukraine, United Kingdom
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Octapharma

Recruiting

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients (Protect-NOW)

Haemophilia A

Belgium, Italy, United States, Azerbaijan, Belarus, Canada, Estonia, France, Germany, Hungary, Lithuania, Russian Federation, Spain, Turkey, United Kingdom, Mexico
Octapharma

Completed

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Significant Bleeding Risk

Russian Federation, United States, Romania, Ukraine, Belarus, Bulgaria, Georgia, Germany, Moldova, Republic of, Poland, Spain
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab

Multiple Myeloma

Korea, Republic of, Russian Federation, Spain, Germany, Belgium, Denmark, Greece, France, United States, Ukraine, Poland
Janssen Research & Development, LLC

Completed

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Multiple Myeloma

United States, Australia, France, Spain, Israel, India, Romania, Korea, Republic of, Singapore, Russian Federation, Poland
Takeda

Recruiting

A Study of Real Life Treatment for Multiple Myeloma (MM) (LEADER)

Multiple Myeloma

Russian Federation
Novo Nordisk A/S

Completed

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A (pathfinder™2)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, Japan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Puerto Rico, Norway, Korea, Republic of, Bulgaria, Russian...
Octapharma

Completed

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Severe Hemophilia A

Canada, United States, France, Spain, Ukraine, United Kingdom, Belarus, Georgia, Germany, India, Italy, Moldova, Republic of, Morocco, Poland, Portugal, Russian Federation, Slovenia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) (EXIST-1)

Tuberous Sclerosis | Subependymal Giant Cell Astrocytoma

United States, Belgium, Canada, Germany, Italy, Russian Federation, Netherlands, Poland, Australia, United Kingdom
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)

Neurofibromatosis 1 | Plexiform Neurofibroma (PN)

United States, Canada, France, Italy, Germany, China, United Kingdom, Spain, Japan, Russian Federation, Australia, Poland, Brazil
Baxalta now part of Shire

Completed

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

Von Willebrand Disease

United States, Spain, Australia, Taiwan, Czechia, Turkey, Ukraine, Netherlands, Italy, United Kingdom, Austria, Germany, Russian Federation
Bayer

Completed

BAY81-8973 Pediatric Safety and Efficacy Trial

Haemophilia A

Spain, Russian Federation, United States, Hungary, Italy, Mexico, Norway, Romania, Bulgaria, Canada, Argentina, Denmark, Israel, Poland, Ireland, Latvia, Lithuania
Catalyst Biosciences

Terminated

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

United States, United Kingdom, Taiwan, Italy, Spain, India, Turkey, Malaysia, Russian Federation, Armenia, Georgia, Hungary, Mexico, Poland, South Africa, Ukraine
Bayer

Completed

A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A (Leopold II)

Hemophilia A

China, United States, Ukraine, Taiwan, Mexico, Thailand, Romania, Colombia, Turkey, Serbia, Russian Federation, South Africa, Japan, Indonesia, Argentina, Czech Republic, India, Slovakia
CSL Behring

Completed

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Hemophilia A

United States, Australia, Austria, Canada, Czech Republic, Germany, Hungary, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
Amgen

Completed

A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma (FOCUS)

Multiple Myeloma

France, Poland, United Kingdom, Belgium, Germany, Spain, Israel, Serbia, Australia, Greece, Korea, Republic of, Russian Federation, Hungary, Sweden, Austria, Slovakia, Italy, Czechia, New Zealand
Novartis Pharmaceuticals

Completed

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) (EXIST-2)

Lymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)

United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Von Willebrand Disease

United States, Belgium, Spain, Italy, Turkey, Germany, Austria, France, Czechia, Russian Federation, Ukraine, United Kingdom, Netherlands
Baxalta now part of Shire

Completed

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Von Willebrand Disease

Netherlands, Spain, United States, Belgium, Australia, United Kingdom, Austria, Italy, Bulgaria, Japan, Poland, Germany, India, Canada, Russian Federation, Sweden
Boehringer Ingelheim

Completed

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Hemorrhage

United States, Spain, United Kingdom, Norway, Taiwan, Israel, Belgium, Australia, Sweden, Singapore, Germany, Italy, New Zealand, Austria, Japan, Canada, Czechia, Portugal, Netherlands, Korea, Republic of, France, Poland, Colombia, Hong... and more
Janssen-Cilag Ltd.
Legend Biotech

Completed

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (LocoMMotion)

Multiple Myeloma

Belgium, United States, United Kingdom, Italy, Germany, Netherlands, Spain, France, Russian Federation, Poland
Celgene

Completed

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Multiple Myeloma

Canada, Denmark, Australia, Belgium, France, Germany, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom, Czechia, Greece
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Severe Hemophilia B

Sweden, United States, France, Italy, Russian Federation, United Kingdom, Germany, China, Poland, Japan, Australia, Brazil, Canada, India, South Africa, Hong Kong, Belgium
GlaxoSmithKline

Recruiting

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM5)

Multiple Myeloma

United States, Australia, France, Japan, Netherlands, Poland, Spain, Sweden, Greece, Canada, Korea, Republic of, Germany, Brazil, Israel, Mexico, Norway, Russian Federation
Hoffmann-La Roche

Completed

A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas

Basal Cell Carcinoma

United States, Spain, France, Germany, Netherlands, Russian Federation, Italy, Mexico, Austria, Canada
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (guardian™ 3)

Congenital Bleeding Disorder | Haemophilia A

United States, Macedonia, The Former Yugoslav Republic of, Serbia, Malaysia, Brazil, Turkey, Lithuania, Russian Federation, Italy, Japan, Poland, Puerto Rico, Taiwan
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors (STASEY)

Hemophilia A

Canada, Australia, Belgium, India, Germany, Israel, Italy, Spain, Colombia, United Kingdom, Netherlands, Saudi Arabia, Hungary, Guatemala, Russian Federation, Poland, Switzerland, Finland, Panama, Brazil, Mexico, Portugal, Romania, Sw...
Pfizer

Active, not recruiting

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Hemophilia A | Hemophilia B

United States, Spain, Canada, China, Korea, Republic of, Hong Kong, Serbia, Taiwan, Turkey, France, Oman, Saudi Arabia, Japan, India, South Africa, Mexico, Croatia, Italy, Bulgaria, Russian Federation
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

Multiple Myeloma

United States, Australia, France, United Kingdom, Germany, Israel, Turkey, Netherlands, Canada, Russian Federation, Czechia
AEterna Zentaris
Dana-Farber Cancer Institute

Terminated

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Multiple Myeloma

Israel, Spain, Korea, Republic of, United States, Russian Federation, Canada, Ireland, Czechia, Slovakia
Janssen Research & Development, LLC

Terminated

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Multiple Myeloma

Canada, United States, Belgium, Poland, Italy, France, Spain, Brazil, Russian Federation, Denmark, Greece, Germany, Netherlands
Janssen Research & Development, LLC

Completed

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, France, Poland, United Kingdom, Belgium, Spain, Germany, Portugal, Bulgaria, Romania, Netherlands, Greece, Canada, Russian Federation, Hungary, Brazil, Slovakia, Czechia
Janssen Research & Development, LLC

Approved for marketing

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Multiple Myeloma

United States, United Kingdom, Spain, Brazil, Russian Federation, Japan
Celgene Corporation

Completed

A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, United Kingdom, Italy, Switzerland, Bulgaria, Poland, Ukraine, Belgium, Germany, Hungary, Ireland, Israel, Russian Federation
Janssen Research & Development, LLC

Completed

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, Poland, Ukraine, Germany, Spain, Turkey, Korea, Republic of, Brazil, Russian Federation, Netherlands, Hungary, Sweden, Czechia, Mexico
Novo Nordisk A/S

Completed

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 (paradigm™ 4)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Russian Federation, Turkey, Japan, South Africa, Romania
Celgene Corporation

Completed

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

Newly Diagnosed Multiple Myeloma

Spain, Netherlands, Austria, Australia, Italy, Russian Federation, United Kingdom, Israel, Belgium, Greece, Germany, Poland, Turkey, France, Denmark, Czech Republic, Belarus, Georgia, Ireland, Sweden, Switzerland, Ukraine
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
Celgene

Completed

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study (NIMBUS)

Multiple Myeloma

United States, Netherlands, Canada, Belgium, United Kingdom, Australia, Denmark, Germany, Spain, Switzerland, France, Italy, Greece, Russian Federation, Sweden, Czechia
Novartis Pharmaceuticals

Active, not recruiting

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Tuberous Sclerosis Complex

United States, Spain, Belgium, Taiwan, Turkey, Australia, Korea, Republic of, Thailand, France, Hungary, United Kingdom, Italy, Japan, Canada, Russian Federation, Poland, Mexico, Colombia
Oncopeptides AB

Terminated

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN)

Multiple Myeloma

United States, Austria, Belgium, Czechia, Denmark, Estonia, France, Greece, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Netherlands, Norway, Poland, Romania, Russian Federation, Spain, Taiwan, United Kingdom
pharmaand GmbH

Completed

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma (PANORAMA_3)

Multiple Myeloma

Canada, Spain, United States, Czechia, Turkey, France, Sweden, Korea, Republic of, Thailand, Belgium, Greece, Germany, Hungary, Russian Federation, Italy, Poland, Australia, Lebanon, Portugal, Norway, Brazil, Netherlands
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) (AHEAD)

Hemophilia A

Czechia, Switzerland, Denmark, Canada, Australia, Austria, France, United Kingdom, Italy, Sweden, Belgium, Brazil, China, Colombia, Greece, Hungary, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain

Clinical Trials on Hereditary Hemorrhagic Telangiectasia in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations